Cargando…

A Simple Platform for the Rapid Development of Antimicrobials

Recent infectious outbreaks highlight the need for platform technologies that can be quickly deployed to develop therapeutics needed to contain the outbreak. We present a simple concept for rapid development of new antimicrobials. The goal was to produce in as little as one week thousands of doses o...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Stephen Albert, Domenyuk, Valeriy, Gupta, Nidhi, Batista, Milene Tavares, Lainson, John C., Zhao, Zhan-Gong, Lusk, Joel F., Loskutov, Andrey, Cichacz, Zbigniew, Stafford, Phillip, Legutki, Joseph Barten, Diehnelt, Chris W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730575/
https://www.ncbi.nlm.nih.gov/pubmed/29242618
http://dx.doi.org/10.1038/s41598-017-17941-7
Descripción
Sumario:Recent infectious outbreaks highlight the need for platform technologies that can be quickly deployed to develop therapeutics needed to contain the outbreak. We present a simple concept for rapid development of new antimicrobials. The goal was to produce in as little as one week thousands of doses of an intervention for a new pathogen. We tested the feasibility of a system based on antimicrobial synbodies. The system involves creating an array of 100 peptides that have been selected for broad capability to bind and/or kill viruses and bacteria. The peptides are pre-screened for low cell toxicity prior to large scale synthesis. Any pathogen is then assayed on the chip to find peptides that bind or kill it. Peptides are combined in pairs as synbodies and further screened for activity and toxicity. The lead synbody can be quickly produced in large scale, with completion of the entire process in one week.